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Abstract  
Possible interactions of melatonin with concurrently administered drugs were investigated in 
in vitro studies utilising human hepatic post-mitochondrial preparations; similar studies were 
conducted with rat preparations to ascertain whether rat is a suitable surrogate for human. 
Drugs were selected based on the knowledge that the 6-hydroxylation of exogenous 
melatonin, its principal pathway of metabolism, is mainly mediated by hepatic CYP1A2, but 
also on the likelihood of the drug being concurrently administered with melatonin. Hepatic 
preparations were incubated with either melatonin or 6-hydroxymelatonin in the presence and 
absence of a range of concentrations of interacting drug, and the production of 6-
sulphatoxymelatonin monitored using a radio-immunoassay procedure. Of the drugs 
screened, only the potent CYP1A2 inhibitor 5-methoxypsoralen impaired the 6-melatonin 
hydroxylation at pharmacologically relevant concentrations, and is likely to lead to clinical 
interactions; diazepam, tamoxifen and acetaminophen (paracetamol) did not impair the 
metabolic conversion of melatonin to 6-sulphatoxymelatonin at concentrations attained 
following therapeutic administration. 17-Ethinhyloestradiol appeared not to suppress the 6-
hydroxylation of melatonin but inhibited the sulphation of 6-hydroxymelatonin, but this is 
unlikely to result in an interaction following therapeutic intake of the steroid. Species 
differences in the inhibition of melatonin metabolism in human and rat hepatic post-
mitochondrial preparations were evident implying that the rat may not be an appropriate 
surrogate of human in such studies 
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Introduction 
Melatonin (N-acetyl-5-methoxytryptamine) is a versatile pineal hormone secreted during 
darkness that has been implicated in a wide variety of physiological functions, including 
regulation of circadian rhythms [1], control of seasonal reproduction [2], modulation of 
insulin secretion [3], immune function [4,5], retinal function [6] and neuroprotection [7]. 
Melatonin is extensively metabolised primarily through hydroxylation at the 6-
position, catalysed selectively by the microsomal CYP1A2 enzyme of the cytochrome P450 
superfamily, which is localised in the liver, with minor contributions from CYP2C19,  
CYP1A1 and CYP1B1, the latter two enzymes being largely extrahepatic [8-10]. The 
generated 6-hydroxymelatonin is subsequently conjugated with sulphate or glucuronide and 
excreted in the urine. Another important metabolite is N-acetylserotonin which is formed by 
O-demethylation, and may represent as much as 20% of the dose [11]. At least in the rat, 
mitochondrial cytochromes P450 can also metabolise melatonin, once again the primary 
metabolite being 6-hydroxymelatonin; the main contributors to the mitochondrial metabolism 
of melatonin are CYP3A and CYP2C6 [12]. Because of its rapid metabolism, melatonin is 
characterised by a short half-life of about an hour that limits its use. However, there is a 
marked inter-individual variation in plasma levels of melatonin following oral administration 
which can be as extensive as 25-fold [13-15]. It has been proposed that in genetically poor 
CYP1A2 metabolisers the plasma levels are much higher as a result of suppressed 
metabolism, giving rise to a longer half-life [16]. High plasma levels may explain the loss of 
pharmacological response to exogenous melatonin following long-term intake [17]. 
Melatonin is an effective phase shifting agent or ‘chronobiotic’ and has been used 
successfully in the treatment of circadian rhythm disorders such as jet lag, shift work, delayed 
sleep phase insomnia [18-20] and non 24 h sleep/wake disorder suffered by the totally blind 
[21]. Its ability to reduce sleep latency has led to its use in primary insomnia [22,23].  
Moreover, it is also an established potent antioxidant acting not only by scavenging reactive 
oxygen/nitrogen species [24] but by additionally up-regulating the synthesis of antioxidant 
enzymes such as glutathione peroxidase and superoxide dismutase, and by increasing the 
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cellular concentration of the nucleophilic tripeptide glutathione [25, 26]. By virtue of its 
antioxidant activity, melatonin has been shown to protect against DNA damage and suppress 
cellular proliferation, and may function as an anticancer agent capable of suppressing all 
three stages of carcinogenesis, namely initiation, promotion and progression [27-29]. 
Moreover, melatonin has been proposed as a possible neuroprotective drug in the treatment of 
conditions such as Parkinson’s disease and Alzheimer’s disease [30]. Finally, melatonin has 
been shown to enhance the effectiveness and attenuate the toxicity of anticancer cytotoxic 
drugs [31-33]. 
As a result of the diversity of its biological activities, and in particular its sleep-
promoting potential, melatonin use is extensive. In many countries, such as the USA, it is 
available over the counter whereas in others, including the United Kingdom, is only available 
on prescription. The increased use of melatonin raises the possibility of interactions with 
other co-administered drugs following modulation of CYP1A2. Pharmacological plasma 
levels of melatonin may be influenced as a result of concurrent exposure to chemicals, 
including drugs that modulate the expression of CYP1A2, the principal catalyst of its 
metabolic degradation. Increased CYP1A2 activity will lead to lower plasma levels and vice 
versa. For example, plasma melatonin levels were increased following fluvoxamine 
administration [34], presumably by impairing its cytochrome P450-mediated metabolism [35, 
36]; fluvoxamine is a potent inhibitor of CYP1A2 [37] and to a lesser extent of CYP2C19 
[38]. Exogenous serum melatonin levels were suppressed by smoking, especially when the 
levels of the hormone were high [39]. Polycyclic aromatic hydrocarbons, a class of 
carcinogenic compounds present in tobacco, up-regulate CYP1A2 expression leading to 
accelerated melatonin metabolism. Similarly, concomitant consumption of caffeine whose 
metabolism is principally catalysed by CYP1A2, more than doubled plasma levels and 
increased the bioavailability of melatonin, by impairing its presystemic metabolism [40]. 
Moreover, drugs that are CYP2C19 substrates such as omeprazole, lansoprazole and 
citalopram, increased the urinary excretion of 6-sulphatoxymelatonin in individuals taking 
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exogenous melatonin; presumably these compounds decrease the CYP219-mediated 
metabolism of melatonin to acetylserotonin [41].  
As the consumption of melatonin continues to rise, the likelihood of interactions with other 
drugs as a consequence of cytochrome P450 modulation increases. In the present study we 
investigated the potential of drugs co-administered with melatonin to influence its 6-
hydroxylation and subsequent conjugation in human hepatic post-mitochondrial preparations. 
As melatonin is available in many countries without prescription, it is likely to be consumed 
concurrently with a wide array of other drugs. . In the current study, the first to address this 
issue, it was considered prudent to select drugs based on two criteria. Firstly drugs that may 
be taken with melatonin on a long-term basis, e.g. 17-ethinyloestradiol present in the 
contraceptive pill, and secondly drugs that are known to interact with CYP1A2 as substrates 
or inhibitors, e.g. 5-methoxypsoralen, this being the principal catalyst of melatonin 6-
hydroxylation both in rats and human [9,10], the major pathway of its metabolism. 
 
Materials and methods 
Acetaminophen (paracetamol), diazepam, 17α-ethinyloestradiol, 5-methoxypsoralen, 
tamoxifen, melatonin, 6-hydroxymelatonin, fluvoxamine maleate and all cofactors were 
purchased from Sigma-Aldrich (Poole, Dorset, UK). The antibody to 6-sulphatoxymelatonin, 
raised in sheep, was a generous gift from Stockgrand Ltd., University of Surrey, Guildford. 
 Three male Wistar albino rats (200-250 g) were purchased from B&K Universal Ltd. 
(Hull, East Yorkshire, UK), and housed in a 12:12 hour light: dark cycle (LD; lights on at 
06.00 h).  Animals were killed by cervical dislocation, livers were removed and 
postmitochondrial supernatant (S9) was prepared by differential centrifugation and stored in 
1 ml aliquots at -20C until use. The protein concentration was determined by the method of 
Lowry et al. [42]. Human liver from a 47-year old male Caucasian who died as a result of 
subarachnoid haemorrhage was obtained from the Peterborough Hospital Human Research 
Tissue Bank; he was a smoker and drank alcohol.  The tissue was delivered snap-frozen in 
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ice, and was stored at -80C.  Post-mitochondrial supernatant (S9) was prepared by 
differential centrifugation as for the rat.  The study received approval from the University of 
Surrey Ethics Committee.    
Determination of melatonin 6-hydroxylase activity in hepatic preparations was 
achieved by measuring its sulphate conjugate, as we have previously described [10]. 
Essentially melatonin (25 nmole) was added into an incubation system comprising a 
NADPH-generating system, adenosine 3´-phosphate 5´-phosphosulphate (PAPS, 50 nmole) 
and 50 l of hepatic post-mitochondrial fraction. Incubation was carried out at 37 °C for 20 
minutes. Reaction was terminated by the addition of 0.2 M perchloric acid (250 l) and 
protein was precipitated by centrifugation at 2500 x g for 15 minutes. The levels of 6-
sulphatoxymelatonin were determined by a validated radioimmunoassay procedure [43]. The 
sulphate conjugation of 6-hydroxymelatonin was determined using the above incubation 
procedure, except that melatonin was replaced with its 6-hydroxy metabolite. Drugs that were 
not water soluble were dissolved in either dimethylsulfoxide or ethanol at a final 
concentration of 1% (v/v). In preliminary studies (results not shown), the generation of 6-
sulphatoxymelatonin from either melatonin or 6-hydroxymelatonin was not modulated by 
these solvents at the concentrations used. 
Results are expressed as mean  SEM.  One-way ANOVA (SPSS, version 10) was 
performed to test for statistically significant differences between the groups, followed by 
Tukey post-hoc when significance was found.   
 
Results 
The formation by human hepatic S9 of 6-sulphatoxymelatonin from both melatonin and 6-
hydroxymelatonin was linear with incubation time for at least one hour. Similarly, with both 
substrates, formation of 6-sulphatoxymelatonin was linear with S9 concentration at least up 
to 200 µl per incubation (results not shown). The 6-sulphatoxymelatonin generation by rat S9 
has already been validated [10]. 
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 Fluvoxamine suppressed the formation of 6-sulphatoxymelatonin from melatonin by 
rat S9 in a concentration-dependent manner, statistical significance being achieved at 
concentrations of 50 µM or higher (Figure 1A); no such inhibition was noted when melatonin 
was replaced with 6-hydroxymelatonin (Figure 1B).  
 5-Methoxypsoralen at a concentration as low as 5 µM, significantly suppressed the 
conversion of melatonin to 6-sulphatoxymelatonin by rat liver S9 (Figure 2A).  At the highest 
concentrations (> 500 µM), 5-methoxypsoralen also caused a significant inhibition in the 
generation of 6-sulphatoxymelatonin from 6-hydroxymelatonin (Figure 2B).  When rat liver 
S9 was substituted by human liver S9 the inhibition of 6-sulphatoxymelatonin formation from 
melatonin was more markedly impaired. It was observed that 5-methoxypsoralen, at 
concentrations as low as 0.01 µM, significantly decreased the production of 6-
sulphatoxymelatonin from melatonin (Figure 2C).  On the other hand, the inhibitory effect on 
the formation of 6-sulphatoxymelatonin from 6-hydroxymelatonin was evident only at 50 µM 
concentration, and was relatively modest (Figure 2D).   
 Diazepam at concentrations of 50 µM and higher caused a significant concentration-
dependent inhibition of the production of 6-sulphatoxymelatonin from melatonin in rat liver 
postmitochondrial fractions (Figure 3A).  In contrast, when 6-hydroxymelatonin was used as 
substrate, diazepam significantly inhibited the generation of 6-sulphatoxymelatonin only at 
the 500 µM concentration (Figure 3B). When human liver postmitochondrial fractions 
replaced the rat fractions, diazepam at the highest concentrations used, namely 100 µM and 
500 µM, impaired the formation of 6-sulphatoxymelatonin from melatonin (Figure 3C).  
When 6-hydroxymelatonin served as substrate, the production of 6-sulphatoxymelatonin was 
also significantly decreased, but only at the highest concentration (500µM) of diazepam used 
(Figure 3D). The effect, however, appeared less pronounced than when melatonin was used 
as substrate.   
 Tamoxifen at the two highest concentrations tested (500 M and 1000 M) 
significantly suppressed the generation of 6-sulpatoxymelatonin from melatonin when rat 
postmitochondrial fractions were utilised (Figure 4A) but no inhibition was evident when 6-
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hydroxymelatonin was used as substrate (Figure 4B).   Following incubation with human 
hepatic postmitochondrial preparations, tamoxifen had no effect on the amount of 6-
sulphatoxymelatonin produced from either melatonin (Figure 4C) or 6-hydroxymelatonin 
(Figure 4D).   
 Acetaminophen, at high concentrations (50 M), decreased the amount of 6-
sulphatoxymelatonin generated by rat liver from either melatonin (Figure 5A) or 6-
hydroxymelatonin (Figure 5B). In contrast, in human liver acetaminophen failed to show any 
significant inhibitory effect on the generation of 6-sulphatoxymelatonin from either 
melatonin (Figure 5C) or 6-hydroxymelatonin (Figure 5D).    
 17-Ethinyloestradiol potently inhibited the metabolism of melatonin to 6-
sulphatoxymelatonin, significant inhibition being evident at concentrations as low as 1 µM, 
the lowest concentration employed in the current studies; the effect of 17-ethinyloestradiol 
was concentration dependent (Figure 6A).  In contrast, no inhibitory effect was observed 
when 6-hydroxymelatonin served as substrate (Figure 6B). In human liver, 17-
ethinyloestradiol at concentrations of 5 µM and higher gave rise to a marked and 
concentration-dependent inhibition of the generation of 6-sulphatoxymelatonin from 
melatonin (Figure 6C). In contrast to the rat, however, 17-ethinyloestradiol also impaired 
the sulphation of 6-hydroxymelatonin (Figure 6D).  
 
Discussion 
The increasing use of melatonin co-administered with other drugs raises the possibility of 
interactions leading to elevated melatonin levels. The selection of drugs to be studied that 
could potentially interact with melatonin was based on the knowledge that the 6-
hydroxylation of exogenous melatonin, its principal pathway of metabolism, is mainly 
mediated by hepatic CYP1A2 in both rats and humans [9, 10], but also on the likelihood of 
the drug being concurrently administered with melatonin. The metabolism of melatonin was 
determined using a validated, sensitive radio-immunoassay procedure that monitors the 
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generation of the sulphate conjugate of 6-hydroxymelatonin, 6-sulphatoxymelatonin [10, 43]. 
In order to discern the effects of the drugs on the cytochrome P450-mediated 6-hydroxylation 
of melatonin from its subsequent sulphate conjugation, the effects of the drugs on the 
generation of 6-sulphatoxymelatonin from 6-hydroxymelatonin were also investigated. 
Moreover, to ascertain whether rat is a suitable surrogate for human in investigating drug 
interactions resulting from cytochrome P450 modulation studies were also carried out in this 
species; this is based on the premise that CYP1A2, responsible for the 6-hydroxylation of 
melatonin in both species, is phylogenetically conserved so that the human protein shares 
extensive structural similarity and displays similar substrate specificity to the rat protein [44].  
In preliminary studies, it was established that the rate of formation of 6-
sulpatoxymelatonin by human post-mitochondrial preparations from 6-hydroxymelatonin was 
orders of magnitude higher compared with melatonin indicating that the sulphation step is not 
rate-limiting, in agreement with our previous studies using rat preparations [10].  
 The antidepressant fluvoxamine was used as a positive control; it is an established 
potent inhibitor of CYP1A2 [36], and early work showed that a single dose of fluvoxamine 
increased the nocturnal production of endogenous melatonin in humans indicating for the first 
time that fluvoxamine and melatonin may interact [34].  Moreover, there is experimental 
evidence that its co-administration with melatonin increases human plasma melatonin levels 
by 6-fold and the area under the curve (AUC) by 9-fold, most likely due to inhibition of its 
metabolism [36].  Inhibition of the 6-hydroxylation was confirmed in the present study using 
rat hepatic preparations and a 50µM melatonin concentration, but the effect was evident only 
at concentrations of 50 µM or higher. In a clinical setting the concentration of both drugs 
would be expected to be <0.1 µM [45] [37], so that the metabolism of melatonin may be 
impaired leading to a rise in plasma levels.  
 Of the drugs employed in the present study, 5-methoxypsoralen, a drug employed in 
the treatment of psoriasis, was clearly the most potent causing almost complete impairment of 
melatonin metabolism at a concentration of 0.1 µ M, with inhibition being observed even at 
0.01 µM, the lowest concentration studied. The sulphate conjugation of 6-hydroxymelatonin, 
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however, was not modulated at these 5-methoxypsoralen concentrations allowing us to 
conclude that the cytochrome P450-mediated hydroxylation is the susceptible pathway. It has 
already been reported that exposure to 5-methyxpsoralen elevates plasma levels of 
endogenous and exogenous melatonin [46-48]. A very interesting observation was that the rat 
necessitated a far higher concentration (5 µM) of 5-methoxypsoralen for inhibition to be 
manifested. As no such difference was noted when 6-hydroxymelatonin served as the 
substrate, the difference may be attributed to the cytochrome P450-catalysed hydroxylation of 
melatonin. It is thus apparent that human CYP1A2 may be more sensitive to 5-
methoxypsoralen-inhibition compared with the rat orthologous protein. The potent inhibition 
of melatonin metabolism by 5-methoxypsoralen may reflect the fact that it is a mechanism-
based inhibitor in both rat and human liver microsomes, i.e. it is first metabolically converted 
to a reactive metabolite that interacts covalently with the haem and/or protein moiety of 
cytochrome P450 resulting in loss of activity [49]. It is conceivable that the higher sensitivity 
of human melatonin metabolism compared with rat probably represents more effective 
generation of the metabolite by the former. Since 5-methoxypsoralen, at therapeutic doses, is 
able to inhibit the CYP1A2-mediated caffeine metabolism in psoriasis patients [50], it is 
likely that the 6-hydroxylation of exogenous melatonin is similarly suppressed.  It is pertinent 
to point out that the mean 5-methoxypsoralen plasma concentration after a standard oral dose 
reaches 1.75 µM [51]; this concentration is markedly higher than the concentration of 0.01 
M that elicited inhibition of melatonin 6-hydroxylase activity in the current study.  
 Marked, concentration-dependent, inhibition of melatonin metabolism to 6-
sulphatoxymelatonin was also observed with the oral contraceptive steroid 17α-
ethinyloestradiol, in both rat and human post-mitochondrial preparations. However, a species 
difference was evident when 6-hydroxymelatonin served as the substrate, with only the 
human activity being impaired; thus the suppression of melatonin metabolism to 6-
sulphatoxymelatonin in the rat may be attributed to impairment of the initial hydroxylation 
reaction. However, in human it appears that the conjugation reaction accounts for the marked 
drop in the formation of 6-sulphatoxymelatonin from melatonin.  17-ethinyloestradiol is 
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extensively sulphated [52] and the sulphate is primarily a storage form of this oestrogen, thus 
it is feasible that the steroid may competitively inhibit sulphation of 6-hydroxymelatonin in 
human post-mitochondrial preparations. Mean serum ethinyloestradiol levels following 30 
mg administration were reported to be about 0.5 nM [53], which is much lower than the 
concentration that caused impairment in the metabolism of melatonin (1 M) in the current 
study so that at clinically relevant concentrations (< 10 nM) it is unlikely to impair the 
sulphate conjugation of exogenous melatonin. However, the much lower endogenous levels 
of melatonin may be impaired by 17α-ethinyloestradiol and such a mechanism may explain to 
some extent why melatonin levels during the night are higher in females taking oral 
contraceptives [54-56].  Since 17- ethinyloestradiol appeared to decrease the sulphate 
conjugation of 6-hydroxymelatonin, it would be advisable in studies assessing melatonin 
treatment to exclude volunteers that use oral contraceptives as it could influence their 
melatonin profiles.  
 Diazepam suppressed the metabolism of melatonin to 6-sulphatoxymelatonin at 
concentrations higher than 50 and 100 µM in rat and human liver microsomes respectively. 
Since in both rat and human liver high concentrations of diazepam impaired the sulphation of 
6-hydroxymelatonin, it may be inferred that the decrease in the conversion of melatonin to 6-
sulphatoxymelatonin is largely a consequence of a less efficient sulphate conjugation. It is 
pertinent to point out that CYP3A4 is the principal catalyst of diazepam metabolism in 
humans [57], so that competitive inhibition is unlikely.  Steady-state plasma concentrations of 
diazepam are about 1.2 µM [58] which is much lower than the required concentration to 
impair the sulphate conjugation of 6-hydroxymelatonin, thus concomitant use of diazepam 
with melatonin will not impair the metabolism of the hormone. 
 A species difference was evident when tamoxifen, a widely used drug in the treatment 
of breast cancer, was investigated, as it impaired rat, but not human, melatonin 6-hydroxylase 
activity.  This lack of effect in human liver could possibly be attributed to the minor 
contribution of CYP1A2 in human hepatic tamoxifen metabolism [59]; to our knowledge, the 
contribution of CYP1A2 in tamoxifen metabolism in the rat has not been reported.  On the 
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basis that the inhibition occurred only in the rat liver and at high concentrations, it may be 
predicted that administration of tamoxifen would be unlikely to impair the metabolism of 
melatonin when administered concomitantly. It is of interest that melatonin has been used in 
combination with tamoxifen in order to increase the effectiveness of the anticancer agent 
[60]. 
 Similar to tamoxifen, acetaminophen (paracetamol) inhibited the conversion of 
melatonin to 6-sulphatoxymelatonin only in the rat, as a result of impaired sulphate 
conjugation of 6-hydroxymelatonin.  It is possible that acetaminophen impairs melatonin 
metabolism in the rat due to the formation of the reactive N-acetyl-p-benzoquinone imine, 
which covalently binds to proteins.  This is possibly the reason why inhibition was observed, 
at both the oxidation and sulphation pathways of melatonin metabolism, and only at high 
concentrations, as at low concentrations the reactive intermediate is probably detoxified by 
glutathione conjugation [61].  The lack of activity of human liver may represent poor 
cytochrome P450-generation of the reactive imine by the human liver, and/ or that the 
detoxification of the reactive metabolite by glutathione may be more efficient in human liver 
compared with rat.    
 Species differences in the inhibition of  melatonin metabolism  in human and rat 
hepatic post-mitochondrial preparations was evident implying that the rat may not be an 
appropriate surrogate of human in such studies. Of all the drugs screened for their potential to 
inhibit melatonin 6-hydroxylation in the present study, only the potent CYP1A2 inhibitor 5-
methoxypsoralen is likely to impair this metabolic pathway in humans, whereas diazepam, 
tamoxifen and acetaminophen are unlikely to display such an effect.  17-Ethinyloestradiol 
appeared not to impair the 6-hydroxylation but to inhibit the sulphation of exogenous 
melatonin in human liver, although this is unlikely to be manifested in vivo since the plasma 
concentration following therapeutic intake is not sufficient to impair the sulphation of 
melatonin.  This inhibitory effect of 17α-ethinyloestradiol could be beneficial, especially in 
individuals with low plasma melatonin levels, leading to a prolonged pharmacological of the 
hormone.   
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Legends to figures 
Figure 1: Effect of fluvoxamine on the generation of 6-sulphatoxymelatonin from (A) 
melatonin and (B) 6-hydroxymelatonin by rat liver post-mitochondrial supernatant.  
 Results are presented as mean ± SEM for triplicate determinations.  *** p < 0.001 compared 
with vehicle control. 
 
Figure 2: Effect of 5-methoxypsoralen on the generation of 6-sulphatoxymelatonin from 
melatonin and 6-hydroxymelatonin by rat and human liver post-mitochondrial 
supernatant.   
Rat liver post-mitochondrial preparations were incubated with (A) melatonin and (B) 6-
hydroxymelatonin. Human liver post-mitochondrial preparations were incubated with (C) 
melatonin and (D) 6-hydroxymelatonin. Results are presented as mean ± SEM for triplicate 
determinations. *p<0.05; ** p < 0.01; *** p<0.001 compared with vehicle control (Veh). 
 
Figure 3: Effect of diazepam on the generation of 6-sulphatoxymelatonin from 
melatonin and 6-hydroxymelatonin by rat and human liver post-mitochondrial 
supernatant.   
Rat liver post-mitochondrial preparations were incubated with (A) melatonin and (B) 6-
hydroxymelatonin. Human liver post-mitochondrial preparations were incubated with (C) 
melatonin and (D) 6-hydroxymelatonin. Results are presented as mean ± SEM for triplicate 
determinations. *p<0.05; *** p<0.001 compared with vehicle control (Veh).  
 
Figure 4: Effect of tamoxifen on the generation of 6-sulphatoxymelatonin from 
melatonin and 6-hydroxymelatonin by rat and human liver post-mitochondrial 
supernatant.   
Rat liver post-mitochondrial preparations were incubated with (A) melatonin and (B) 6-
hydroxymelatonin. Human liver post-mitochondrial preparations were incubated with (C) 
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melatonin and (D) 6-hydroxymelatonin. Results are presented as mean ± SEM for triplicate 
determinations. *p<0.05 compared with vehicle control (Veh) 
 
Figure 5: Effect of acetaminophen on the generation of 6-sulphatoxymelatonin from 
melatonin and 6-hydroxymelatonin by rat and human liver post-mitochondrial 
supernatant.   
Rat liver post-mitochondrial preparations were incubated with (A) melatonin and (B) 6-
hydroxymelatonin. Human liver post-mitochondrial preparations were incubated with (C) 
melatonin and (D) 6-hydroxymelatonin. Results are presented as mean ± SEM for triplicate 
determinations. *p<0.05; ** p < 0.01; *** p<0.001 compared with vehicle control (Veh) 
 
Figure 6: Effect of 17α-ethinyloestradiol on the generation of 6-sulphatoxymelatonin 
from melatonin and 6-hydroxymelatonin by rat and human liver post-mitochondrial 
supernatant.   
Rat liver post-mitochondrial preparations were incubated with (A) melatonin and (B) 6-
hydroxymelatonin. Human liver post-mitochondrial preparations were incubated with (C) 
melatonin and (D) 6-hydroxymelatonin. Results are presented as mean ± SEM for triplicate 
determinations. *p<0.05; ** p < 0.01; *** p<0.001 compared with vehicle control (Veh) 
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Highlights 
 
 The potential of melatonin to interact with other drugs was investigated in human 
liver microsomes 
 After incubation with melatonin/6-hydroxymelatonin, 6-sulphatoxymelatonin was 
monitored 
 5-Methoxypsoralen impaired the 6- hydroxylation of melatonin 
 17-Ethinhyloestradiol inhibited the sulphation of 6-hydroxymelatonin 
